Oncopeptides secures Slovenian maximum allowed price for Pepaxti in regulatory pricing decision

Reuters2026/08/17 08:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Oncopeptides secured a Maximum Allowed Price for Pepaxti in Slovenia, a regulatory pricing decision required before reimbursement talks.
The MAP was set by Slovenia’s medicines agency JAZMP, enabling market-access negotiations with health insurer ZZZS.
The list price was published in Slovenia’s central medicines database effective Aug. 15, 2026.
Management flagged Slovenia as a reference market for pricing across Central and Eastern Europe, shaping broader regional rollout plans.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncopeptides AB published the original content used to generate this news brief on August 17, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Oncopeptides secures Slovenian maximum allowed price for Pepaxti in regulatory pricing decision

You may also like

Crypto prices